Difference between revisions of "Template:HypericumInfo"

From Psychiatrienet
Jump to: navigation, search
 
(8 intermediate revisions by 4 users not shown)
Line 1: Line 1:
* Hypericum induces enzymes of the CYP P-450 type and P-gp type.
+
* Hypericum induces enzymes of the [[wp:Cytochrome P450 reductase|CYP P-450]] type and P-gp type.
* Hypericum probably has MAO-inhibiting and/or COMT-inhibiting properties.
+
* Hypericum might have [[wp:Monoamine oxidase inhibitor|MAO-inhibiting]] and/or [[wp:COMT inhibitor|COMT-inhibiting]] properties.  
 +
* Many studies reported that hypericin is the main source of pharmacological effects of hypericum. However the IC50 of hypericin to inhibit MAO A and MAO B is 100- to 1000-fold higher than accessible Cmax values of hypericin after oral administration of hypericum.<ref name ="Wurglics2006">{{Pubmed|16640452|Wurglics M, Schubert-Zsilavecz M.Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.}}</ref>

Latest revision as of 15:11, 4 August 2023

  • Hypericum induces enzymes of the CYP P-450 type and P-gp type.
  • Hypericum might have MAO-inhibiting and/or COMT-inhibiting properties.
  • Many studies reported that hypericin is the main source of pharmacological effects of hypericum. However the IC50 of hypericin to inhibit MAO A and MAO B is 100- to 1000-fold higher than accessible Cmax values of hypericin after oral administration of hypericum.[1]
  • Wurglics M, Schubert-Zsilavecz M.Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.